article
How GPCR agonists, including antibodies, are shaping the future of metabolic care
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
List view / Grid view
Therapeutics
news
New collaboration targets key challenges in fibrosis treatment
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
news
Injectable gel targets osteoarthritis pain
Hydrocelin shows promising preclinical results in treating osteoarthritis, offering pain relief and potential joint protection with no observed side effects.
article
In vivo CAR T: Faster, cheaper, and more effective cancer care
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
news
Refeyn launches software platform to automate mass photometry workflows
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
news
Novartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
news
New CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
news
USC partners with Autobahn Labs to accelerate drug discovery
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
article
Leveraging agonist antibodies to address immunological diseases
Therapeutic antibodies play a key role in addressing unmet medical needs. Here, Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and…
podcasts
Leveraging “omics” for novel microbiome drug concepts
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
news
Suppression of neuropeptide F extends longevity in flies
The relationship between insulin and ageing in flies could have far-reaching implications for diabetes and obesity drugs for humans.
news
Proscia: advancing pathology AI development
Proscia has launched two new products which will help to accelerate discovery and development of new therapies and diagnostics.
article
Combining precision bispecific antibodies with targeted radiotherapy
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander…
news
KRAS variants in human pancreatic cancer: new key findings
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.